GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipca Laboratories Ltd (BOM:524494) » Definitions » EPS (Diluted)

Ipca Laboratories (BOM:524494) EPS (Diluted) : ₹22.25 (TTM As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Ipca Laboratories EPS (Diluted)?

Ipca Laboratories's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was ₹7.09. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹22.25.

Ipca Laboratories's EPS (Basic) for the three months ended in Dec. 2023 was ₹7.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹22.25.

Ipca Laboratories's EPS without NRI for the three months ended in Dec. 2023 was ₹5.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₹19.55.

During the past 12 months, Ipca Laboratories's average EPS without NRIGrowth Rate was -5.00% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -9.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Ipca Laboratories's highest 3-Year average EPS without NRI Growth Rate was 69.20% per year. The lowest was -34.30% per year. And the median was 18.95% per year.


Ipca Laboratories EPS (Diluted) Historical Data

The historical data trend for Ipca Laboratories's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipca Laboratories EPS (Diluted) Chart

Ipca Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.61 23.98 45.01 34.85 18.58

Ipca Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 3.02 6.42 5.72 7.09

Competitive Comparison of Ipca Laboratories's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's PE Ratio distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's PE Ratio falls into.



Ipca Laboratories EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Ipca Laboratories's Diluted EPS for the fiscal year that ended in Mar. 2023 is calculated as

Diluted EPS (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(4713.2-0)/253.704
=18.58

Ipca Laboratories's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1798.8-0)/253.709
=7.09

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹22.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipca Laboratories  (BOM:524494) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ipca Laboratories EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Ipca Laboratories's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipca Laboratories (BOM:524494) Business Description

Traded in Other Exchanges
Address
125, Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a specialty and generic drug manufacturing company. The company's principal activity is Development, Manufacturing and Marketing of Pharmaceuticals Products. The company operates multiple subsidiaries with revenue generation split roughly between India and the rest of the world. Ipca's products are exported to more than 100 countries across the globe. Ipca has only one reportable primary business segment, pharmaceuticals.

Ipca Laboratories (BOM:524494) Headlines

No Headlines